The 4T1M3OVA group excluded intrinsic tumor interference, as differences of Bax/ Bcl-2/ Ki67 compared with CD8+ TOT−1-treated 4T1M3OVA tumors were significantly smaller than those between the two CD8+ TOT−1-treated tumor groups, demonstrating that these changes of these indicators were due to the different cytotoxic effects of CD8+ TOT−1 cells (Fig. S4L&M). The gene discussed is BCL2; the disease is neoplasm.